title: Serum amino-terminal propeptide of type III procollagen and 7S domain of type IV collagen correlate with hepatic iron concentration in patients with chronic hepatitis C following alpha-interferon therapy.
abstract: BACKGROUND
  It has been reported that chronic infection with hepatitis C virus is associated with excess iron deposits in the liver of subjects who are neither alcoholics nor recipients of blood transfusions. However, little is known about the relationship between hepatic iron concentration (HIC) and the serum levels of hepatic fibrogenesis markers, which were caused by interferon therapy for chronic hepatitis C. Therefore, changes in the serum amino-terminal propeptide of type III procollagen (P-III-P) and the 7S domain of type IV collagen (7S-IV) in 16 patients treated with alpha-interferon (IFN-alpha) were studied, and their HIC and histological assessment evaluated. Hepatic iron concentrations were measured by using liver biopsy specimens obtained before and 6 months after the cessation of treatment.
  
  
  RESULTS
  Eight subjects (50%) who had normal alanine transaminase levels at 6 months after therapy showed significantly lowered HIC, and attenuated hepatic iron staining with decreased serum levels of P-III-P and 7S-IV compared to the remaining subjects. The HIC was significantly correlated with the serum levels of P-III-P and 7S-IV in all subjects.
  
  
  CONCLUSIONS
  These findings suggest that IFN-alpha treatment may decrease stimuli for fibrogenesis, at least in part, by reducing the hepatic iron deposition in patients with chronic hepatitis C.
authors.affiliation: Second Department of Internal Medicine, Tokushima University School of Medicine, Japan. shimizui@clin.med.tokushima-u.ac.jp
authors.forename: I
authors.initials: I
authors.lastname: Shimizu
authors.forename: T
authors.initials: T
authors.lastname: Omoya
authors.forename: T
authors.initials: T
authors.lastname: Takaoka
authors.forename: S
authors.initials: S
authors.lastname: Wada
authors.forename: H
authors.initials: H
authors.lastname: Wada
authors.forename: M
authors.initials: M
authors.lastname: Taoka
authors.forename: H
authors.initials: H
authors.lastname: Hayashi
authors.forename: S
authors.initials: S
authors.lastname: Hayashi
authors.forename: H
authors.initials: H
authors.lastname: Honda
authors.forename: N
authors.initials: N
authors.lastname: Sano
authors.forename: S
authors.initials: S
authors.lastname: Ito
mesh_terms: D000328:Adult; D003094:Collagen / Q000097:blood*; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D006820:Hyaluronic Acid / Q000097:blood; D016898:Interferon-alpha / Q000627:therapeutic use*; D007501:Iron / Q000032:analysis*; D008099:Liver / Q000737:chemistry*; D008297:Male; D008875:Middle Aged; D011347:Procollagen / Q000097:blood*; D017434:Protein Structure, Tertiary
chemical_list: D016898:Interferon-alpha; D011347:Procollagen; D006820:Hyaluronic Acid; D003094:Collagen; D007501:Iron